Table 2.
Bortezomib use in AIHA.
| Study type | AIHA type | Population | N | Thermal features | Comments | References |
|---|---|---|---|---|---|---|
| Case report | CAD with MGUS | Adult (78 years) | 2 | Cold | • Bortezomib single agent 1.3 mg/sqm for three doses • Response: CR (N = 2) • No toxicity |
Carson et al. 23 |
| Case report | Secondary to SLE | Adult (60 years) | 1 | Warm | • Bortezomib 1.3 mg/sqm on days 1, 4, 8 + cyclophosphamide + dexamethasone • Response: CR • Toxicity: G1 thrombocytopenia and G3 neutropenia |
Danchaivijitr et al. 24 |
| Case report | Secondary to umbilical cord blood HSCT for AML | Adult (28 years) | 1 | Warm | • Bortezomib single agent 1.3 mg/sqm for four doses • Response: NR • No toxicity • Death for massive hemolysis (d + 318) |
Rovira et al. 25 |
| Case report | ES secondary to HSCT for SCID | Pediatric (1.25 and 2.3 years) | 2 | Unknown | • Bortezomib single agent 1.3 mg/sqm on days 1, 4, 8 and 11 • Response: CR (N = 2) • Unknown if toxicity |
Khandelwal et al. 26 |
| Case report | Secondary to HSCT for SCID | Pediatric (4 months) | 1 | Warm IgG + C |
• Bortezomib single agent 1.3 mg/sqm IV on days 1, 4, 8 and 11 • Response: CR • No toxicity |
Mehta et al. 27 |
| Case report | ES secondary to HSCT for ALL | Pediatric (1 year) | 1 | Unknown | • Bortezomib 1.3 mg/sqm IV on days 1, 4, 9, 12, 23 and 26 + vincristine + prednisolone • Response: CR • Toxicity: peripheral neuropathy |
Waespe et al. 28 |
| Case report | Secondary to HSCT for post-MDS AML | Adult (46 years) | 1 | Warm | • Bortezomib single agent 1.3 mg/sqm sc weekly for four doses • Response: PR • No toxicity |
Hosoba et al. 29 |
| Case report | Secondary to SLE | Adult (65 years) | 1 | Warm IgG + C |
• Bortezomib single agent 1.3 mg/sqm/week for four doses • Response: CR • No toxicity |
Wang et al. 30 |
| Case report | Primary | Adult (47–81 years) | 8 | Warm (N = 6) Cold (N = 2) |
• Bortezomib 1.3 mg/sqm on days 1, 4, 8 and 11 for one to maximum 13 cycles • Response: CR (N = 1), PR (N = 5), NR (N = 2) • Toxicity: G1 diarrhea (N = 1), G3 hepatotoxicity in the context of high alcohol intake |
Ratnasingam et al. 22 |
| Clinical trial | 12 primary, 9 secondary (3 CLL, 6 B-NHL) | Adult | 21 | Cold | • Bortezomib single agent 1.3 mg/sqm IV on days 1, 4, 8 and 11 • Response: evaluable for response (N = 19): CR (N = 3), PR (N = 3), NR (N = 13); Median follow-up: 16 months • Toxicity: G1-2, N = 13; G3-4, N = 6 (headache, diarrhea, increased bilirubin, anemia, pulmonary embolism) |
Rossi et al. 31 |
| Case report | Secondary to cryoglobulinemic vasculitis | Adult (72 years) | 1 | Cold | • Bortezomib 1.3 mg/sqm on days 1, 8, 15 and 22 + cyclophosphamide + dexamethasone every 35 days for two courses • Response: CR • No toxicity |
Liu et al. 32 |
| Case report | CAD with IgA/λ MGUS | Adult (60 years) | 1 | Cold | • Bortezomib 1.3 mg/sqm/week for 3 weeks + rituximab (375 mg/sqm/week) + dexamethasone (20 mg on days 1, 2, 8, 9, 15 and 16) for four cycles • Response: CR • No toxicity |
Sefland et al. 33 |
| Case report | Primary | Adult (83 years) | 1 | Warm | • Bortezomib 1.3 mg/sqm for four doses in combination with rituximab • Response: CR • No toxicity |
Ames et al. 34 |
| Case report | Secondary to low-grade B-NHL (N = 2), Hodgkin lymphoma (N = 2), SLE (N = 2); 2 of them ES | Adult (median age 48.5 years) | 8 | Warm | • Bortezomib single agent 1.3 mg/sqm on days 1, 4, 8 and 11 in combination with dexamethasone • Response: CR (N = 3), PR (N = 3), NR (N = 2) • Toxicity: G2 peripheral neuropathy (N = 2) and thrombocytopenia (N = 2), G5 death for sepsis with multiple organ failure (N = 1) |
Fadlallah et al. 35 |
| Case report | Secondary to combined liver-small bowel-pancreas transplant | Pediatric (4 years) | 1 | Unknown | • Bortezomib 1.3 mg/sqm on days 1, 4, 8 and 11 for six administrations • Response: complete remission • Toxicity: increased ileal stoma output, G1-2 neutropenia and thrombocytopenia, increased transaminases |
Knops et al. 36 |
AIHA, autoimmune hemolytic anemia; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; B-NHL, B-cell non-Hodgkin lymphoma; CAD, cold agglutinin disease; CLL, chronic lymphocytic leukemia; CR, complete response; ES, Evans syndrome; HSCT, hematopoietic stem cell transplant; IgG, immunoglobulin G; IV, intravenous; MDS, myelodysplastic syndrome; MGUS, monoclonal gammopathy of undetermined significance; NR, non-response; PR, partial response; SCID, severe combined immunodeficiency; SLE, systemic lupus erythematosus.